Portal de Periódicos da CAPES

Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment

1995; Wiley; Volume: 35; Issue: 6 Linguagem: Inglês

10.1046/j.1537-2995.1995.35695288773.x

1537-2995

Stephen M. Capon, Dennis Goldfinger,

Trauma, Hemostasis, Coagulopathy, Resuscitation

TransfusionVolume 35, Issue 6 p. 513-520 Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment Stephen M. Capon, Stephen M. Capon Stephen M. Capon, MD, Assistant Clinical Professor, Department of Pathology and Laboratory Medicine, University of California, San Diego, School of Medicine, La Jolla, CA.Search for more papers by this authorDennis Goldfinger MD, Corresponding Author Dennis Goldfinger MD Director2Dennis Goldfinger, MD, Director, Rita and Taft Schreiber Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 4526, Los Angeles, CA 90048-1869Search for more papers by this author Stephen M. Capon, Stephen M. Capon Stephen M. Capon, MD, Assistant Clinical Professor, Department of Pathology and Laboratory Medicine, University of California, San Diego, School of Medicine, La Jolla, CA.Search for more papers by this authorDennis Goldfinger MD, Corresponding Author Dennis Goldfinger MD Director2Dennis Goldfinger, MD, Director, Rita and Taft Schreiber Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 4526, Los Angeles, CA 90048-1869Search for more papers by this author First published: June 1995 https://doi.org/10.1046/j.1537-2995.1995.35695288773.xCitations: 45 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Goldfinger D. Acute hemolytic transfusion reactions-a fresh look at pathogenesis and considerations regarding therapy. Transfusion 1977; 17: 85–98. 2 Bing RJ. The effect of hemoglobin and related pigments on renal functions of the normal and acidotic dog. Bull Johns Hopkins Hosp 1944; 74: 161–76. 3 Baker SL, Dodds EC. Obstruction of the renal tubules during the excretion of haemoglobin. Br JExp Pathol 1925; 6: 247. 4 Billiau A., Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991; 21: 559–73. 5 Cannon JG, Tompkins RG, Gelfand FA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84. 6 Davenport RD, Streiter RM, Kunkel SL. Red cell ABO incompatibility and production of tumour necrosis factor-alpha. Br J Haematol 1991; 78: 540–4. 7 Davenport RD, Burdick M., Moore SA, Kunkel SL. Cytokine production in IgG-mediated red cell incompatibility. Transfusion 1993; 33: 19–24. 8 Davenport RD, Streiter RM, Standiford TJ, Kunkel SL. Inter-leukin-8 production in red blood cell incompatibility. Blood 1990; 76: 2439–42. 9 Davenport RD, Burdick M., Streiter RM, Kunkel SL. Monocyte chemoattractant protein production in red cell incompatibility. Transfusion 1994; 34: 16–9. 10 Butler J., Parker D., Pillai R., et al. Systemic release of neutrophil elastase and tumour necrosis factor alpha following ABO incompatible blood transfusion. Br J Haematol 1991; 79: 525–6. 11 Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52. 12 Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588–602. 13 Davenport RD, Burdick M., Streiter RM, Kunkel SL. Interleukin-1 receptor antagonist (IL-lra) production in IgG mediated hemolysis (abstract). Transfusion 1992; 32 (Suppl): 45S. 14 Rapaport SI. Blood coagulation and its alterations in hemorrhagic and thrombotic disorders. West J Med 1993; 158: 153–61. 15 Van der Poll T., Buller HR, Ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622–7. 16 Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128–33. 17 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 3460–4. 18 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–5. 19 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73: 159–65. 20 Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C., an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982; 60: 261–4. 21 Taylor FB Jr, Chang A., Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Esherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918–25. 22 Davenport RD, Polak TJ, Kunkel SL. White cell-associated procoagulant activity induced by ABO incompatibility. Transfusion 1994; 34: 943–9. 23 Fan ST, Edgington TS. Coupling of the adhesive receptor CD1 lb/CD 18 to functional enhancement of effector macrophage tissue factor response. J Clin Invest 1991; 87: 50–7. 24 Davenport RD, Burdick M., Kunkel SL. Endothelial cell activation in hemolytic transfusion reactions (abstract). Transfusion 1992; 32 (Suppl): 53S. 25 Brenner BM, Troy JL, Ballermann BJ. Endothelium-dependent vascular responses. Mediators and mechanisms. J Clin Invest 1989; 84: 1373–8. 26 Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664–6. 27 Yanagisawa M., Kurihara H., Kimura S. et al, A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5. 28 Griendling KK, Lassegue BP, Taylor WR, Alexander RW. Control of vascular tone by the endothelium: new insights. J Crit Illness 1993; 8: 355–70. 29 Kon V., Badr KF. Biological actions and pathophysiologic significance of endothelin in the kidney (editorial). Kidney Int 1991; 40: 1–12. 30 Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1949; 1: 469–89. 31 Hess JR, MacDonald VW, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993; 74: 1769–78. 32 Moncada SR, Palmer MJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 40: 109–42. 33 Goldfinger D., O'Connell M., Ellrodt AG. Pathogenesis and treatment of shock associated with acute hemolytic transfusion reactions (abstract). Transfusion 1985; 25: 468. 34 Tracey KJ, Lowry SF, Cerami A. Cachectin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137: 1377–9. 35 Capon SM, Sacher RA. Hemolytic transfusion reactions: a review of mechanisms, sequelae, and management. J Intensive Care Med 1989; 4: 100–11. 36 Schmidt PJ. Transfusion mortality; with special reference to surgical and intensive care facilities. J Fla Med Assoc 1980; 67: 151–3. 37 Honig CL, Bove JR. Transfusion-associated fatalities: review of Bureau of Biologies reports 1976-1978. Transfusion 1980; 20: 653–61. 38 Rock RC, Bove JR, Nemerson Y. Heparin treatment of intravascular coagulation accompanying hemolytic transfusion reactions. Transfusion 1969; 9: 57–61. 39 Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and posttranscriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139: 4129–34. 40 Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829–35. 41 Tracey KJ, Fong Y., Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4. 42 Van Zee KJ, Kohno T., Fischer E., et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–9. 43 Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445–51. 44 Gershenwald JE, Fong YM, Fahey TJ III et al. Interleukin 1 receptor blockage attenuates the host inflammatory response. Proc Natl Acad Sci U S A 1990; 87: 4966–70. 45 Fanslow WC, Sims JE, Sassenfeld H., et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739–42. 46 Warr TA, Rao LV, Rappaport SI. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989; 74: 994–8. Citing Literature Volume35, Issue6June 1995Pages 513-520 ReferencesRelatedInformation